# A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

> **NCT02754830** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 72 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** LY3303560 - IV
- **DRUG:** Saline Solution - IV
- **DRUG:** LY3303560 - SC

## Key facts

- **NCT ID:** NCT02754830
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-25
- **Primary completion:** 2018-07-10
- **Final completion:** 2018-07-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754830, "A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02754830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*